Resultados da pesquisa - Sekwon Jang

  • A mostrar 1 - 8 resultados de 8
Refinar resultados
  1. 1
    Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report

    Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report Por Masood Sadaat, Sekwon Jang

    Publicado em 2018
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  2. 2
    Smoking and quality of life among female survivors of breast, colorectal and endometrial cancers in a prospective cohort study

    Smoking and quality of life among female survivors of breast, colorectal and endometrial cancers in a prospective cohort study Por Sekwon Jang, Anna E. Prizment, Tufia C. Haddad, Kim Robien, DeAnn Lazovich

    Publicado em 2010
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  3. 3
    Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma

    Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma Por Sekwon Jang, Chaoyi Zheng, Huei‐Ting Tsai, Alex Z. Fu, Ana Barac, Michael B. Atkins, Andrew N. Freedman, Lori M. Minasian, Arnold L. Potosky

    Publicado em 2015
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  4. 4
    Tumor Regression and Allograft Rejection after Administration of Anti–PD-1

    Tumor Regression and Allograft Rejection after Administration of Anti–PD-1 Por Evan J. Lipson, Serena M. Bagnasco, Jack Moore, Sekwon Jang, Manisha J. Patel, Andrea A. Zachary, Drew M. Pardoll, Janis M. Taube, Charles G. Drake

    Publicado em 2016
    Obter o texto integral Obter o texto integral
    Carta
    Adic. favoritos
    Na minha lista:
  5. 5
    Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms

    Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms Por Charles W. Abbott, Sean M. Boyle, Rachel Marty Pyke, Lee McDaniel, Éric Levy, Fábio C. P. Navarro, Dattatreya Mellacheruvu, Simo V. Zhang, Mengyao Tan, Rose Santiago, Zeid M. Rusan, Pamela Milani, Gábor Bartha, Jason Harris, Rena McClory, M Snyder, Sekwon Jang, Richard Chen

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  6. 6
    Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

    Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma Por Adi Diab, Scott S. Tykodi, Gregory A. Daniels, Michele Maio, Brendan D. Curti, Karl D. Lewis, Sekwon Jang, Ewa Kalinka‐Warzocha, Igor Puzanov, Alexander I. Spira, Daniel C. Cho, Shanhong Guan, Erika Puente-Poushnejad, Tuan Nguyen, Ute Hoch, Sue Currie, Wei Lin, Mary Tagliaferri, Jonathan Zalevsky, Mario Sznol, Michael E. Hurwitz

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  7. 7
    Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

    Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204) Por Hussein A. Tawbi, Peter Forsyth, F. Stephen Hodi, Christopher D. Lao, Stergios J. Moschos, Omid Hamid, Michael B. Atkins, Karl D. Lewis, Reena Thomas, John A. Glaspy, Sekwon Jang, Alain P. Algazi, Nikhil I. Khushalani, Michael A. Postow, Anna C. Pavlick, Marc S. Ernstoff, David A. Reardon, Igor Puzanov, Ragini R. Kudchadkar, Ahmad A. Tarhini, Anne Sumbul, Jasmine I. Rizzo, Kim Margolin

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  8. 8
    Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study

    Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre... Por Hussein A. Tawbi, Peter Forsyth, F. Stephen Hodi, Alain P. Algazi, Omid Hamid, Christopher D. Lao, Stergios J. Moschos, Michael B. Atkins, Karl D. Lewis, Michael A. Postow, Reena Thomas, John A. Glaspy, Sekwon Jang, Nikhil I. Khushalani, Anna C. Pavlick, Marc S. Ernstoff, David A. Reardon, Ragini R. Kudchadkar, Ahmad A. Tarhini, Caroline Chung, Corey Ritchings, Piyush Durani, Margarita Askelson, Igor Puzanov, Kim Margolin

    Publicado em 2021
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:

Ferramentas de pesquisa: